Eli Lilly has hit $1 trillion in market value, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.

A more than 35 percent rally in the company’s stock this year has largely been driven by the explosive growth of the weight-loss drug market and saw it join the $1 trillion club on Friday.

Once seen as a niche category, obesity treatments are now one of the most lucrative segments in healthcare, with steadily rising demand.

Novo Nordisk had the early lead in the space, but Lilly’s drugs – Mounjaro and Zepbound – have surged in popularity and helped eclipse its rival in prescriptions.

The company’s shares were up 1.3 percent at a record high of $1,057.70.

Lilly now trades at one of the richest valuation

See Full Page